Genetic subgroups in MS: Who may progress faster?

Credibility

Interest

Key Takeaway

People with MS can be grouped by genetic patterns that predict how fast disability may progress and whether common treatments are likely to help.

What They Found

Researchers looked at many genetic markers and grouped people with MS into three genetic clusters that shared similar DNA patterns. One group (cluster 1) had slower disability progression, reaching major disability milestones years later than the other two groups. The groups with faster progression (clusters 2 and 3) also showed more new spots on brain scans that are linked to MS activity. In one group (cluster 2), people who got disease-modifying treatments showed a clear delay in reaching a major disability milestone, while the treatments didn’t show the same benefit in the other groups. Some symptoms, like trouble swallowing and muscle tightness, started earlier in one of the faster-progressing groups, suggesting different symptom patterns by genetic group.

Who Should Care and Why

People with MS and their caregivers should care because genetic grouping might help predict how quickly disability could move forward, which affects planning for work, mobility aids, and home changes. Clinicians and MS care teams may use this information to decide who might get more benefit from certain disease-modifying treatments — like choosing a stronger guard for a house that’s at higher risk of break-in. Patients thinking about treatment choices may benefit from genetic testing in the future if it helps identify a group likely to respond. Caregivers can use this knowledge to watch more closely for early signs (for example, swallowing or muscle stiffness) in people at higher risk so they can get help sooner. Health systems and researchers may use these groups to run targeted studies and build more personalized treatment plans, rather than treating everyone the same way.

Important Considerations

The study grouped people based on genetic patterns, but genetics is only one piece of the puzzle—environment, lifestyle, and other health issues also affect MS, so results aren’t the whole story. The findings come from two specific patient groups (a Welsh tracking study and a Dutch brain bank), so we don’t yet know how well the same groups apply to people from other countries or backgrounds. At this stage, genetic clustering is not a ready-made clinical test; it points to promise for more personalized care but needs more study before changing standard treatment for individuals.

Categories:

MS Genetics Treatment Updates MS Progression

Article Topics:

GENETICSMULTIPLE SCLEROSISPrognosis

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology, neurosurgery, and psychiatry often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News